Applied therapeutics, inc. announces pricing of $30 million public offering of common stock and warrants

New york, june 22, 2022 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt) (the “company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of its underwritten public offering of 20.0 million shares of its common stock, par value $0.0001 per share, 10.0 million pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants (“common warrants”) to purchase up to 30.0 million shares of its common stock. each share of common stock and accompanying common warrant are being offered at a combined public offering price of $1.00, less underwriting discounts and commissions, and each pre-funded warrant and accompanying common warrant are being offered at a combined public offering price of $0.9999, less underwriting discounts and commissions. the pre-funded warrants have an exercise price of $0.0001 per share and the common warrants have an exercise price of $1.00 per share. the pre-funded warrants and the common warrants are immediately exercisable and will expire five years from the date of issuance. the gross proceeds to the company from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by the company, are expected to be $30 million.
APLT Ratings Summary
APLT Quant Ranking